Viva Biotech Holdings (VBIZF)
OTCMKTS · Delayed Price · Currency is USD
0.3150
-0.0094 (-2.90%)
At close: Aug 26, 2025
Viva Biotech Holdings Revenue
Viva Biotech Holdings had revenue of 831.87M CNY in the half year ending June 30, 2025, a decrease of -27.17%. This brings the company's revenue in the last twelve months to 1.84B, down -7.94% year-over-year. In the year 2024, Viva Biotech Holdings had annual revenue of 1.99B, down -7.84%.
Revenue (ttm)
1.84B CNY
Revenue Growth
-7.94%
P/S Ratio
2.71
Revenue / Employee
890.31K CNY
Employees
2,063
Market Cap
695.80M USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.99B | -168.93M | -7.84% |
Dec 31, 2023 | 2.16B | -224.05M | -9.42% |
Dec 31, 2022 | 2.38B | 275.55M | 13.10% |
Dec 31, 2021 | 2.10B | 1.41B | 201.90% |
Dec 31, 2020 | 696.96M | 373.90M | 115.74% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Tian'an Technology Group | 2.12M |
Elite Pharmaceuticals | 105.45M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
AMJ Global Technology | 39.00 |
Viva Biotech Holdings News
- 10 days ago - Unlocking the Potential of Cyclic Peptide Therapeutics: Viva Biotech's Discovery Insights - PRNewsWire
- 15 days ago - Viva Biotech Announces Its 2025 Interim Results: CRO Revenue Returned to Positive Growth, New CDMO Commercialization Projects Showed Promising Growth - PRNewsWire
- 6 months ago - Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection - PRNewsWire
- 6 months ago - Viva Biotech Announces 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D - PRNewsWire
- 9 months ago - Viva Biotech Officially Establishes Boston Branch, Marking Another Milestone in Global Expansion - PRNewsWire
- 1 year ago - Viva Biotech Announces Its 2024 Interim Results: Significant Improvement in Net Profit Growth and Ongoing Optimization of Emerging Technology Platforms - PRNewsWire
- 1 year ago - Viva Biotech (1873.HK) Announces 2023 Annual Results: Successful Implementation of Light-asset Strategy, Achieving Solid Growth and Promising Future - PRNewsWire
- 1 year ago - Viva Biotech Secures Approximately US$ 210 Million Funding - PRNewsWire